| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
Platelet aspirin sensitivity assessed by COX-1 activity in severe DM patients was the same as in healthy individuals, which denies the hypothesis that high blood glucose levels interfere with aspirin acetylation of the COX-1 active site. On the other hand, some individuals who showed strong platelet aggregation at high aspirin dose despite their almost complete inhibition of TxA2 production were observed only in the DM group. Such "high residual platelet responsiveness" was corrected by adding P2Y12 receptor blocker, suggesting that P2Y12 blocker in addition to aspirin might be beneficial for selected DM patients.
|
